CETP-Inhibition and HDL-Cholesterol

A Story of CV Risk or CV Benefit, or Both

Research output: Contribution to journalReview ArticleOtherpeer-review

7 Citations (Scopus)

Abstract

Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.

Original languageEnglish
Pages (from-to)297-300
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume104
Issue number2
DOIs
Publication statusPublished - 1 Aug 2018
Externally publishedYes

Cite this

@article{49f6c1c8db4b4732a0eb563708cce26e,
title = "CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both",
abstract = "Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.",
author = "Nicholls, {Stephen J.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/cpt.1118",
language = "English",
volume = "104",
pages = "297--300",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "American Society for Clinical Pharmacology and Therapeutics",
number = "2",

}

CETP-Inhibition and HDL-Cholesterol : A Story of CV Risk or CV Benefit, or Both. / Nicholls, Stephen J.

In: Clinical Pharmacology and Therapeutics, Vol. 104, No. 2, 01.08.2018, p. 297-300.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - CETP-Inhibition and HDL-Cholesterol

T2 - A Story of CV Risk or CV Benefit, or Both

AU - Nicholls, Stephen J.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.

AB - Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.

UR - http://www.scopus.com/inward/record.url?scp=85050967663&partnerID=8YFLogxK

U2 - 10.1002/cpt.1118

DO - 10.1002/cpt.1118

M3 - Review Article

VL - 104

SP - 297

EP - 300

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -